Background: People living with HIV (PLWH) commonly have low bone mineral density (BMD) (low bone mass and osteoporosis) and are at high risk for fractures. Fractures and low BMD are significant causes of morbidity and mortality, increasingly relevant as PLWH age. Alcohol use is common among PLWH and known to affect bone health. The association between alcohol use and changes in BMD among PLWH is not well understood.
P EOPLE LIVING WITH HIV (PLWH) commonly have low bone mineral density (BMD) (low bone mass [formerly referred to as osteopenia] and osteoporosis) and are at high risk for fractures (Brown and Qaqish, 2006; Ventura et al., 2017) . Fractures are substantial causes of morbidity and mortality in general and are becoming more relevant to PLWH as this population continues to age (Arnsten et al., 2007; Hansen et al., 2012; Womack et al., 2011) . PLWH have some of the same risk factors for low BMD as do those without HIV infection, but they also have additional risks, such as HIV infection itself and its treatments, both shown to independently impact bone density (Cotter et al., 2014; Walker Harris and Brown, 2012) . In addition, those with HIV infection are more likely to have other risk factors such as comorbid conditions that impact bone health, such as hepatitis C infection, secondary hyperparathyroidism, smoking, low body mass index (BMI), weight loss, and chronic kidney disease (Casado et al., 2014; Mondy et al., 2003) .
Substance use is common among PLWH, and alcohol, cocaine, and opioid use have all been associated with low BMD (Kim et al., 2006; McComsey et al., 2010; Sharma et al., 2015) . Alcohol has been associated with decreased bone formation, particularly heavy drinking (Chakkalakal, 2005; Friday and Howard, 1991) . Some studies have found that low amounts of alcohol have been associated with higher bone density, but the results of these studies have been inconsistent and inconclusive (Cawthon et al., 2006; Feskanich et al., 1999; Tucker et al., 2009) . Such studies have often had limited measurement of alcohol consumption (Berg et al., 2008) . Thus, it has not been clear whether associations between alcohol use and bone density were directly due to alcohol consumption or to concomitant risk.
We reported results among PLWH from a cross-sectional study of the association between recent and lifetime alcohol use and BMD; although there were no significant associations between lifetime use and BMD, recent alcohol use was associated with lower BMD (Ventura et al., 2017) . However, neither that analysis nor other extant studies have adequately evaluated the association between alcohol consumption and change in bone density and incident fractures among PLWH. Therefore, using validated measures of alcohol consumption, in a population of PLWH and current substance use disorder or ever injection drug use, we prospectively studied the associations between alcohol consumption and both change in BMD and incident fractures adjusting for potential confounders. We hypothesized that greater alcohol consumption would be associated with decreased BMD and more incident fractures. Such information is important for informing patients and clinicians regarding alcohol use and low BMD risks.
MATERIALS AND METHODS

Participants
Participants were enrolled in the Boston ARCH prospective cohort study examining the effect of alcohol on bone health in PLWH with substance use disorder or ever injection drug use. Research participants were recruited from an urban academic HIV primary care clinic based in a hospital and a community health center serving homeless patients from December 2012 to November 2014. Participants were recruited over a 2-year period and had varying maximum planned observation periods given the fixed maximum of 3.5 years of involvement.
Inclusion criteria were as follows: (i) confirmed documentation of HIV infection in any medical record (Massachusetts Department of Public Health algorithm) or HIV viral load >10,000 copies/ml; (ii) past 12-month DSM-IV drug or alcohol use dependence by Mini International Neuropsychiatric Interview (M.I.N.I. 6.0; Sheehan et al., 2010) or ever injection drug use; (iii) ability to speak English; (iv) ≥18 years old; and (5) willingness to provide contact information for 1 or more persons likely to know the participant's whereabouts. Exclusion criteria were as follows: pregnancy, determined by urine test; and plans to leave Boston in the next year. This study population was described in a cross-sectional analysis reported previously that focused on the relationship between recent and lifetime drinking and BMD based on data at study entry only (Ventura et al., 2017) . Due to the longitudinal nature of this study, an additional inclusion criterion specific to the analyses reported herein was all participants had to have BMD measured by DXA at the same bone site 2 or more times during the study period.
Participants provided written informed consent for the study, and they were compensated for each visit. The Boston University Medical Campus Institutional Review Board approved the study. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) further protected participants with a Certificate of Confidentiality. Additionally, the U.S. Department of Health and Human Services approved the follow-up of incarcerated participants.
Assessments of Bone Density, Fractures, and Alcohol Use
Bone density measurements were performed at study entry and at up to 2 annual follow-up visits. As described in Ventura and colleagues (2017) , all measurements were performed by bone densitometry technologists certified by the International Society for Clinical Densitometry. The DXA machines used were as follows: (i) Hologic QDR 4500 Discovery W (software version 12.6.1; Waltham, MA); (ii) Hologic QDR 4500 Discovery W (software version 13.4.2; and (iii) General Electric (GE) Lunar iDXA (GE Healthcare, Madison, WI). The 2 Hologic DXAs (hereafter referred to as Hologic 1 and Hologic 2) were cross-calibrated using a standard phantom. All BMD measurements taken from the GE Lunar iDXA (hereafter referred to as iDXA) were converted to Hologic-equivalent values by applying industry-accepted conversion formulas (Wilson, 2011) . Fractures were assessed by self-report at study entry and at 12-month follow-up ("In the past 12 months, have you fractured or broken a bone?").
We examined alcohol exposure over a 1-year period to match the time period assessed by DXA. Daily alcohol use was assessed at study entry, 6, 12, 18, and 24 months, using the 30-day Timeline Followback (TLFB; a validated interview calendar method for measuring past month daily alcohol use; Sobell and Sobell, 1992) .
Additional Assessments
We assessed the following at study entry by interview: age, biological sex, race/ethnicity, duration of HIV infection, lifetime drinking (total volume) (Skinner and Sheu, 1982) , and years of regular cocaine use (McLellan et al., 1980) . Additionally, we assessed tenofovir use, menopause, ever injection drug use, current tobacco use (Heatherton, et al., 1991) , daily calcium intake (Sebring et al., 2007) , weight-bearing physical activity (Marshall et al., 2005) , recent (30-day) cocaine use (McLellan et al., 1980) , recent illicit opioid use (McLellan et al., 1980) , and current antiretroviral therapy (ART) use. Number of days of cocaine use in past 30 days, and number of days of illicit opioid use (including prescription opioids and nonprescription opioids) in past 30 days were assessed using the Addiction Severity Index (McLellan et al., 1980) . Menopause was evaluated using the following question: "In the past year, have you had menopause (at least 12 months since your last period)?"
At the baseline visit, each study participant's medical record was reviewed for the most recent HIV viral load (copies/ml), and the most recent CD4 cell count (cells/mm 3 ). If unavailable within 3 months before baseline, CD4 and HIV viral load were tested. Blood was additionally tested for total 25-hydroxy-vitamin D [25 (OH)D] by liquid chromatography-tandem mass spectrometry. Height and weight were recorded during the study visit and used to calculate BMI.
Medications and conditions that can affect BMD (e.g., including secondary causes of osteoporosis) were collected from the electronic medical record. Medications that decrease BMD include the following: glucocorticoids (oral and inhaled), anti-asthma (only budesonide/formoterol, fluticasone/salmeterol), anti-inflammatory (inhaled, including beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, fluticasone, mometasone), anticonvulsants (only divalproex, phenytoin, carbamazepine), chemotherapeutic agents, anticoagulants, and depo-provera (Brufsky, 2008; Chee et al., 2014; Drummond et al., 2008; Gbolade, 2002; Lee et al., 2010; Rey-Sanchez et al., 2011; Van Staa et al., 2002) . Medications that increase BMD include denosumab, progestin only, contraceptive (systemic, levonorgestrel), bisphosphonates, androgen/anabolics (testosterone, topical, or transdermal), and estrogen (transdermal, oral) (Caird et al., 1994; Cummings et al., 2009; Manolagas et al., 2002; MunkJensen et al., 1988; Rodriguez-Tolr a et al., 2013; Russell, 2011 44128, 44202, 44203) , and bariatric surgery (43644, 43645, 43659, 43842 to 43848) were also included (McKiernan et al., 2011) .
Primary Outcome Variables
The primary outcome variable was annual change in BMD (g/cm 2 ) measured by DXA at the femoral neck.
Secondary Outcome Variable
Secondary outcomes were annual change in (i) total hip and (ii) lumbar spine BMD, (iii) >6% annual decrease in BMD at any site (Binkley et al., 2006; Stellbrink et al., 2010) , and (iv) any fracture in the past year. Among the 187 participants without osteoporosis at study entry, only 5 newly met criteria at a subsequent assessment; thus, we did not analyze incident osteoporosis as a secondary outcome.
Main Independent Variable
The main independent variable was mean grams per day of alcohol consumption over the previous year. Mean alcohol consumption was calculated by averaging daily alcohol consumption reported at 3 study interviews-for year 1, baseline, 6-month, and 12-month time points; and for year 2, 12-month, 18-month, and 24-month time points. For year 1, 98% had 3 observations and 2 participants were missing 1 observation. Fewer participants were followed through year 2 because the cohort study period ended as planned.
However, for year 2 among those with planned follow-up, 98% had 3 observations and 2 participants were missing 1 observation.
Additional Independent Variables
In addition to mean daily alcohol consumption, the following alcohol measures were calculated: (i) mean number of heavy drinking days per month, based on National Institute on Alcohol Abuse and Alcoholism (NIAAA) heavy drinking day threshold: ≥5 drinks for males and ≥4 drinks for females); (ii) mean number of days abstinent per month; and (iii) any heavy drinking. Past 30-day drinking (assessed every 6 months) was assumed to be the exposure until the next time point for which data were available.
We also defined categories of alcohol use by drinks (0 to <0.7 drinks/d, 0.7 to 1.7 drinks/d, >1.7 drinks/d) (Berg et al., 2008) . Categories based on NIAAA standard thresholds for risky drinking were also developed: (i) abstinence: no drinking in past 30 days; (ii) not heavy: drank, but did not exceed NIAAA daily (≥5 for males and ≥4 for females) or weekly (>14 for males and >7 for females) limits in past 30 days; (iii) heavy or very heavy: exceeded NIAAA daily or weekly limits. Heavy was defined as 0 to 4 days per month exceeding the daily limit. Very heavy was defined as 5 or more days per month exceeding the daily limits.
Covariates
Covariates include all listed above under "additional assessments." To account for the heterogeneity of the study population, we controlled for multiple potential confounders including age, sex, race/ethnicity, duration of HIV infection, NIAAA drinking group, DXA machine used, lifetime drinking volume, years of regular cocaine use, tenofovir use, menopause, ever injection drug use, BMI, current smoker, CD4 cell count, calcium, weight-bearing physical activity, total [25(OH)D] ng/ml, recent cocaine use, recent opioid use, and current ART use. Medications and conditions that can affect BMD were controlled for in sensitivity analyses.
Statistical Analysis
All analyses were conducted using SAS software, version 9.3 (SAS Institute Inc., Cary, NC). Initial analyses focused on testing the association between mean alcohol consumption (g/d over the past year) and annual change in BMD. Adjusted analyses included all covariates above except those highly correlated (r > 0.45). Number of years since initiation of ART was excluded due to high correlation with duration of HIV infection (r = 0.67). HIV viral load suppression (<200/200+ cells/mm 3 ) was excluded due to high correlation with current ART use (r = 0.60). Two pairs of variables (i.e., age and duration of HIV infection; and tenofovir use and current ART) were moderately correlated (r = 0.40 and r = 0.45, respectively) and were included as covariates in the analyses. All other covariate correlations were <0.40.
Primary analyses were mixed effects linear regression models with random intercepts focused on associations between alcohol consumption (measured as grams per day as the primary independent variable) and annual change in femoral neck BMD (dependent variable). Covariates (see above) were selected for inclusion based on either clinical suspicion or statistical significance of their association with alcohol use or change in BMD.
Secondary analyses also included mixed effects linear regression models focused on associations between alcohol use (measured as grams per day as the primary independent variable) and change in total hip BMD, change in lumbar spine BMD. Additional secondary analyses included mixed effects logistic regression models testing the association between alcohol use and the other secondary outcomes: >6% annual decrease in BMD at any site and any fractures in the past year. Additional measures of alcohol use including mean number of heavy drinking days, mean number of days abstinent, mean numbers of drinks per day categorized as 0 to <0.7, 0.7 to 1.7, and >1.7, and consumption over the past month categorized as abstinence, not heavy, heavy, and very heavy, were used as independent variables; secondary analyses explored the relationship between those alcohol measures and secondary bone outcomes.
Additionally, we conducted a number of sensitivity analyses to check the robustness of the primary analysis. Due to the use of multiple DXA machines, a sensitivity analysis was performed for the primary regression model stratified by the DXA used (both tests carried out on Hologic 1; both tests carried out on Hologic 2; first test carried out on Hologic 1 and second on Hologic 2; excluding iDXA tests) (Table S1 ). We also tested an interaction between alcohol use and sex. We also fit the unadjusted model including a squared term for grams of alcohol per day, to determine whether a quadratic model would be appropriate.
To understand the impact of protease inhibitors (PI), we expanded our original ART variable, which previously included (i) tenofovircontaining regimen, (ii) PI, and (iii) all other ART classes. We developed another variable consisting of (i) no ART, (ii) tenofovir and no PI, (iii) tenofovir and PI, (iv) PI and no tenofovir, and (v) other ART (no PI or tenofovir), and fit the primary analysis model for average alcohol use (g/d) and changes in femoral neck BMD adding this new ART variable. To further explore the role of secondary causes of osteoporosis in the relationship between alcohol use and BMD, we created a dichotomous variable for any such condition at baseline and at follow-up to use as a covariate in the primary analysis. Additionally, we performed a sensitivity analysis adding medications with known bone impact as 1 of 2 covariates-medications that increase BMD and medications that decrease BMD.
Third, to understand the role of vitamin D (e.g., if it is on causal pathway, or a covariate), we fit our primary model without total [25 (OH)D]. Also, as there is evidence that Caucasian and Hispanic people, and postmenopausal women have a higher incidence of low BMD we tested the interaction of alcohol and race/ethnicity, and alcohol and sex/menopausal status for the primary model (Hedlund and Gallagher, 1989; Wright et al., 2014) .
In addition to the sensitivity analyses, we conducted exploratory cross-sectional analyses in baseline data (i.e., at study entry) to understand the relationship between alcohol use and bone loss. We analyzed alcohol use (g/d) and the following 3 outcomes: femoral neck BMD (g/cm 2 ); procollagen type 1 amino-terminal propeptide (P1NP; a bone remodeling marker for osteoblast activity); and type I collagen C-telopeptide (CTX-1; a bone remodeling marker for osteoclast activity). Analyses were unadjusted and adjusted for the same covariates as the primary analysis.
The study enrolled 250 adults, anticipating a 20% or lower loss to follow-up. Assuming an evaluable sample of 200 participants with 1 observation per subject, the study had 80% power to detect a difference in means of À3.0% versus À1.9% between those with heavy use and those abstinent or with less than heavy use. The study also had 80% power to detect a significant quadratic trend in the association between alcohol use and change in BMD, assuming uniformly distributed alcohol use (evaluated in simulations before study start which predicted 80 abstainers, 30 drinkers without heavy use (≥5 drinks for males and ≥4 for females), and 150 with heavy alcohol use. As aforementioned, a squared term for alcohol consumption (g/d) was included in a model, to determine whether a quadratic model was justified.
RESULTS
Study Participants
Of 1,460 patients approached, 673 completed screening; 299 did not meet eligibility criteria; the most common reason for ineligibility was that the patient did not have past 12-month alcohol or drug dependence or had never injected drugs (82%). Of the 374 patients who met all eligibility criteria, 250 (67%) enrolled and 234 (94%) participants received ≥2 DXA scans at ≥1 bone sites. Sixteen did not receive ≥2 DXA scans at ≥1 site due to loss to follow-up. Of the 250 cohort participants, follow-up was 99% at 6 months, 96% at 18 months, 95% at 24 months, and 96% at 30 months. Characteristics of study participants are detailed in Tables 1 (baseline) and 2 (over each year of observation).
Demographic Characteristics
At baseline, the median age of participants was 50 years. The study population was predominantly comprised of racial and ethnic minorities: 51% (120) identified as Non-Hispanic Black, and 24% (57) 
Substance Use Characteristics
Approximately half (52% [121]) of the study population exceeded NIAAA daily (≥5 for males and ≥4 for females) or weekly (>14 for males and >7 for females) alcohol limits at study entry; 31% (74) reported past 30-day abstinence. The mean total lifetime alcohol consumption was 720 kg. Over half of the study population (57% [134]) had ever injected drugs. The proportions of participants reporting past 30-day injection, cocaine use and opioid use were 10% (24), 30% (70), and 23% (54), respectively (Table 2) .
Bone Characteristics
At study entry, 67% (154) of participants met criteria for low BMD (low bone mass 46% (107) [at least 1 Tscore at any site between À1 and À2.5] or osteoporosis 21% (47) [T-score ≤À2.5]). T-score represents standard deviation compared with average peak bone mass in young adult men. Among women (82), 55% (45) had low bone mass and 19% (15) 
Secondary Analyses
In unadjusted and adjusted regression analyses, there were no associations between mean alcohol consumption (g/d) and the following secondary outcomes (Table 3) : change in total hip BMD (Adj. b = À0.0009, p = 0.8719), change in lumbar spine BMD (Adj. b = À0.0060, p = 0.4067), >6% annual decrease in BMD at any site (Adj. odds ratio [OR] = 1.00, 95% confidence interval [CI] = 0.99, 1.01), and any fractures in the past year (Adj. OR 0.99, 95% CI = 0.98, 1.01). Additional measures of alcohol consumption, including mean number of heavy drinking days, mean number of days abstinent, mean number of drinks per day categorized as 0 to <0.7, 0.7 to 1.7, and >1.7, and consumption over the past month categorized as abstinence, not heavy, heavy, and very heavy, were not associated with changes in femoral neck, total hip, and lumbar spine BMD. The aforementioned additional measures were not associated with >6% annual decrease in BMD at any site, or any fractures in the past year. (96) 39.4% (50) ART, antiretroviral therapy; BMI, body mass index; BMD, bone mineral density; IQR, interquartile range; PI, protease inhibitors; PLWH, people living with HIV; SD, standard deviation. Glucocorticoids (oral and inhaled), anti-asthma (only budesonide/formoterol, fluticasone/salmeterol), anti-inflammatory (inhaled, including beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, fluticasone, mometasone), anticonvulsants (only divalproex, phenytoin, carbamazepine), chemotherapeutic agents, anticoagulants, and depo-provera. j Primary hyperparathyroidism (252.01, 252.0), secondary, tertiary, unspecified, or ectopic hyperparathyroidism (252.00, 252.02, 252.08, 259.3, 252 .0), Cushing's syndrome (255), hyperthyroidism, Graves ' disease, toxic goiter (242.00, 242.0 to 242.4, 242.8, 242.90) , male hypogonadism (257.1 to 257.2), premature menopause (256.2, 256.31, 256.39, 626.0, 627.4) , hyperprolactinemia (253.1), acromegaly (253), panhypopituitarism (253.2), osteomalacia, hypovitaminosis D (268.0 to 268.9), celiac disease, sprue (579.0 to 579.1), malnutrition, malabsorption (263.0, 263.1, 263.9, 579.3, 579.8, 579.9 ), Crohn's disease (555.0 to 555.9), ulcerative colitis (556.0 to 556.9), anorexia, bulimia nervosa (307.1, 307.51), primary biliary cirrhosis (571.6) chronic liver disease, cirrhosis (571.9), hemochromatosis (275), chronic kidney disease (585.0 to 585.6, 585.9), renal hyperparathyroidism (588.81, 588.8), renal osteodystrophy (588) 
OR ( 
Sensitivity Analyses
We conducted a number of sensitivity analyses to check the robustness of the primary analysis. A sensitivity analysis addressing type of machine and software version yielded results similar to the result of the primary analysis (Table S2 ). In the unadjusted quadratic model, a squared term for alcohol consumption (g/d) was not significant (b = À0.0001, p = 0.4504). There was no significant interaction between alcohol consumption and sex (p = 0.4097). There was no significant interaction between alcohol, race, and menopausal status (p = 0.2060), and alcohol and sex/ menopausal status (p = 0.3538).
To understand the impact of PI, we expanded the ART variable and fit the primary analysis model for average alcohol use (g/d) and changes in femoral neck BMD. The results were similar to those with the original ART variable (Adj. b = À0.0032, p = 0.7491).
To further explore the role of secondary causes of osteoporosis in the relationship between alcohol use and BMD, we included a dichotomous variable for any secondary cause of osteoporosis at baseline and at follow-up to use as a covariate in the primary analysis, which did not affect the primary finding (Adj. b = À0.0032, p = 0.7436). Similarly, to account for other concomitant treatments with known bone impact, we performed a sensitivity analysis adding the 2 variables representing medications (that increase, or that decrease BMD) from data obtained from the electronic medical record. We fit the primary analysis model with these new variables, which did not affect the primary finding (Adj. b = À0.0027, p = 0.7820). Removing vitamin D status as covariate did not impact the primary analysis finding (Adj. b = À0.0036, p = 0.7112).
Exploratory Analyses
In addition to the sensitivity analyses, we repeated the primary analysis of alcohol use cross-sectionally at baseline and did not find any significant association between average alcohol exposure (g/d) and femoral neck BMD (b = À0.00004, p = 0.8475, Adj. b = À0.0001, p = 0.5050). We repeated the same cross-sectional analysis at baseline assessing the association between alcohol use and 2 bone marker outcomes: (P1NP and CTX-1). There was a significant association between alcohol use and P1NP (b = À0.1130, p = 0.0043, Adj. b = À0.1033, p = 0.0304), but no significant association between alcohol use and CTX-1 (b = À0.0018, p = 0.00852, Adj. b = À0.0013, p = 0.2604).
DISCUSSION
The main aim of this study was to assess the association between alcohol consumption and annual changes in BMD among PLWH and substance use disorders. We expected to find that higher alcohol consumption would be associated with decreased BMD. However, unexpectedly, although two-thirds of PLWH with substance use disorders had low BMD, and alcohol use may increase risk for low BMD, we did not detect any effects of drinking on change in BMD or incident fractures. A number of sensitivity analyses yielded similar findings. There was no significant finding in exploratory cross-sectional analyses. There was a significant association between alcohol use and P1NP (more alcohol, less bone formation) but no significant association between alcohol use and CTX-1, which is consistent with findings in the literature (Alvisa-Negrin et al., 2009; Gonzalez-Calvin et al., 1993; Maurel et al., 2012; Nyquist et al., 1996) . However, the clinical significance of this latter finding is unclear and the association between alcohol and bone formation and resorption has been mixed and inconclusive in other studies, possibly due to other co-existing factors such as smoking, vitamin D deficiency, and gastrointestinal diseases (Maurel et al., 2012; Turner, 2000) .
Although the cohort had a broad range of alcohol use, change in alcohol use was small. Relatively static alcohol consumption may have limited our ability to detect changes in BMD. Multiple competing risks may partially explain the null results; the prevalence of secondary causes of low BMD (e.g., smoking, opioid use), was high among the study population, and similar to that reported in other studies (Bonjoch et al., 2010; Brown et al., 2008) . Consequently, it is possible that an effect of alcohol use was not detectable in the setting of concomitant risks.
These findings should be placed in the context of prior literature assessing alcohol consumption and bone outcomes in PLWH. In previous work, we did not detect an association between lifetime alcohol consumption and BMD although there was an association between current alcohol consumption and BMD; these analyses, however, were cross-sectional (Ventura et al., 2017) . In cohort studies, high alcohol consumption has been associated with an increased risk of fracture in PLWH (Collin et al., 2009; Womack et al., 2011) . In a 10-year cohort study of 1,281 PLWH, the incidence rate of fractures was 2.9-fold higher among those with excessive alcohol consumption (Collin et al., 2009) . However, studies have not consistently found alcohol to increase risk for low BMD in PLWH (Bedimo et al., 2018; Brown et al., 2009; Carr et al., 2015; Cazanave et al., 2008; Escota et al., 2016; Gill et al., 2014; Grund et al., 2009; Kasonde et al., 2014; Kooij et al., 2015; Mondy et al., 2003; Sharma et al., 2010; Yin, 2012) . Many of these studies used measures of alcohol consumption that may not be very accurate or specific (e.g., medical record reviews, or self-report measures that have not been validated), did not adjust for covariates related to bone health outcomes, and had short follow-up periods. In the present study, we used a validated measure of alcohol use (Sobell and Sobell, 1992) , adjusted for numerous potential confounding factors (e.g., smoking, opioid use, antiretroviral medication, BMI, and CD4 count), and followed PLWH for up to 3½ years.
Our findings are subject to several study limitations. Study participants had current substance use disorder, or ever injection drug use, and were largely well connected to clinical HIV care. Therefore, our findings may be most generalizable to other care-engaged PLWH with substance use disorders. Although adjusted for numerous confounders, it remains possible that there was unadjusted confounding. One possibility is that ongoing inflammation related to alcohol use and to HIV infection (Carrico et al., 2015; Hunt et al., 2016; Kuller et al., 2008) even among those virally suppressed might play a role as a confounder. We did not collect information about the first exposure to medications that could affect BMD, when the risk of bone loss is most pronounced (Canalis et al., 2007) . We did collect information about years since initiation of ART but did not include it as a covariate in regression analyses because it was highly correlated with duration of HIV infection. Additionally, our analyses included time-varying covariates representing ART exposure and other medications that can affect BMD. Therefore, we do not believe that this limitation is likely to have a substantial impact on the findings. Alcohol consumption was assessed by self-report, which may be influenced by recall and social desirability biases. However, we used the 30-day TLFB method (Sobell and Sobell, 1992) , which is widely accepted as the best-validated method for assessing selfreported consumption, and we do not have reason to suspect that the aforementioned biases would be related to bone outcomes. Fractures were assessed by self-report, which may be influenced by recall bias. However, fractures are memorable events; people may not recall precise details of timing, but they do likely remember fracture occurrence. Self-reported fractures have a sensitivity of 78%, and a specificity of 96% when compared to medical record documented fractures (Honkanen et al., 1999; Ismail et al., 2000; Nevitt et al., 1992) . Another important limitation is that the alcohol measures obtained at 6-month intervals did not assess drinking beyond the past month. However, these repeated assessments captured and summarized daily drinking in a number of ways, and these detailed validated assessments of recent consumption likely reflect interim periods.
Although we measured BMD in a standardized fashion using DXA, we used 3 different machines, which could introduce measurement error; measurements can vary as much as 11% (Fan et al., 2010) . To minimize this measurement error, we used an industry-accepted conversion formula to account for between-machine differences, controlled for DXA machine and software in regression models, and performed a sensitivity analysis by DXA machine. Finally, it is possible that the observation time (2 years) for the cohort was too short to detect any effects of alcohol on BMD. However, other studies have detected changes in BMD and incidence in osteoporotic fractures due to alcohol and other risk factors (e.g., ART) in shorter or comparable periods ranging from 6 months to 2 years (Arnsten et al., 2007; Avihingsanon et al., 2017; Duvivier et al., 2009; Hoy et al., 2017; Kasonde et al., 2014; Mondy et al., 2003; Rey et al., 2015; Sharma et al., 2010; Siris et al., 2001; Young et al., 2011) . Given the observed effect sizes, preplanned study power to detect fairly small effects, and loss to follow-up much lower than planned, we do not believe power limitations are a likely explanation for the null findings.
At least among PLWH with multiple risk factors, alcohol use may not have a very large effect on BMD. Examining this question in a sample with greater change in alcohol use and fewer competing risks is worthy of consideration. But given the high prevalence of both low BMD and risk factors for it, understanding and addressing it in PLWH and the role that reversible causes play should remain a priority. The population of PLWH is now aging, thanks to efficacious treatments for HIV infection itself, and common comorbidities associated with aging and their treatments are emerging as the main contributors to overall health for PLWH. Low BMD and its fracture consequences remain of great importance along with other comorbidities such as substance use, cardiovascular disease, and neurologic diseases. Furthermore, given that PLWH and substance use disorder are also at high risk for injury and fracture, concerns regarding low BMD go beyond immune dysfunction, inflammation, and direct medication and substance effects on bone.
CONCLUSIONS
In this sample of PLWH with substance use disorder or ever injection drug use, we detected no effects of alcohol consumption on annual change in BMD or incident fractures. Larger diverse samples with longer follow-up may be able to discern the specific effects of alcohol as well as effects of multiple risk factors (e.g., alcohol combined with other exposures). Thus, although we did not find effects, we cannot conclude that alcohol is safe even from the perspective of bone health for PLWH and substance use disorders.
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